View : 34 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author김경효-
dc.date.accessioned2019-07-29T16:31:07Z-
dc.date.available2019-07-29T16:31:07Z-
dc.date.issued2018-
dc.identifier.issn0022-1899-
dc.identifier.issn1537-6613-
dc.identifier.otherOAK-22590-
dc.identifier.urihttp://dspace.ewha.ac.kr/handle/2015.oak/250291-
dc.description.abstractBackground. A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002). Methods. Participants (N = 2519) were vaccinated at day 1 and months 2 and 6. Gynecological samples (Study 001 only) and serum were collected for HPV DNA and antibody assessments, respectively. Injection-site and systemic adverse events (AEs) were monitored. Data were analyzed by country and vaccination group. Results. 9vHPV vaccine prevented HPV-31/33/45/52/58-related persistent infection with 90.4%-100% efficacy across included countries. At month 7, >= 97.9% of participants seroconverted for each HPV type. Injection-site AEs occurred in 77.7%-83.1% and 81.9%-87.5% of qHPV and 9vHPV vaccine recipients in Study 001, respectively, and 62.4%-85.7% of girls/boys in Study 002; most were mild to moderate. Conclusions. The 9vHPV vaccine is efficacious, immunogenic, and well tolerated in Asian participants. Data support 9vHPV vaccination programs in Asia.-
dc.languageEnglish-
dc.publisherOXFORD UNIV PRESS INC-
dc.subject9vHPV-
dc.subjectAsia-
dc.subjectcervical cancer-
dc.subjecthuman papillomavirus-
dc.subjectvaccine-
dc.titleEfficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries-
dc.typeArticle-
dc.relation.issue1-
dc.relation.volume218-
dc.relation.indexSCI-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.startpage95-
dc.relation.lastpage108-
dc.relation.journaltitleJOURNAL OF INFECTIOUS DISEASES-
dc.identifier.doi10.1093/infdis/jiy133-
dc.identifier.wosidWOS:000434930900012-
dc.identifier.scopusid2-s2.0-85048443828-
dc.author.googleGarland, S. M.-
dc.author.googlePitisuttithum, P.-
dc.author.googleNgan, H. Y. S.-
dc.author.googleCho, C-H-
dc.author.googleLee, C-Y-
dc.author.googleChen, C-A-
dc.author.googleYang, Y. C.-
dc.author.googleChu, T-Y-
dc.author.googleTwu, N-F-
dc.author.googleSamakoses, R.-
dc.author.googleTakeuchi, Y.-
dc.author.googleCheung, T. H.-
dc.author.googleKim, S. C.-
dc.author.googleHuang, L-M-
dc.author.googleKim, B-G-
dc.author.googleKim, Y-T-
dc.author.googleKim, K-H-
dc.author.googleSong, Y-S-
dc.author.googleLalwani, S.-
dc.author.googleKang, J-H-
dc.author.googleSakamoto, M.-
dc.author.googleRyu, H-S-
dc.author.googleBhatla, N.-
dc.author.googleYoshikawa, H.-
dc.author.googleEllison, M. C.-
dc.author.googleHan, S. R.-
dc.author.googleMoeller, E.-
dc.author.googleMurata, S.-
dc.author.googleRitter, M.-
dc.author.googleSawata, M.-
dc.author.googleShields, C.-
dc.author.googleWalia, A.-
dc.author.googlePerez, G.-
dc.author.googleLuxembourg, A.-
dc.contributor.scopusid김경효(35448653000)-
dc.date.modifydate20190729144243-
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE